We are live on ! Find out more
BTAI icon

BioXcel Therapeutics
BTAI

19 hedge funds and large institutions have $25M invested in BioXcel Therapeutics in 2018 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

0.19% less ownership

Funds ownership: 1.49% → 1.3% (-0.19%)

5% less funds holding

Funds holding: 20 → 19 (-1)

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

27% less capital invested

Capital invested by funds: $34.2M → $25M (-$9.21M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
19
Holders Change
-1
Holders Change %
-5%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
6
Increased
5
Reduced
4
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Squarepoint
Squarepoint
New York
+$172K
2
AIM
Artemis Investment Management
United Kingdom
+$152K
3
Creative Planning
Creative Planning
Kansas
+$124K
4
Morgan Stanley
Morgan Stanley
New York
+$37K
5
Deutsche Bank
Deutsche Bank
Germany
+$28.8K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.23M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$434K
3
Millennium Management
Millennium Management
New York
-$421K
4
PAM
Prudence Asset Management
Hong Kong
-$272K
5
MWNA
Marshall Wace North America
New York
-$174K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$10.1M -$3.23M -21,771 -21%
AIM
2
Artemis Investment Management
United Kingdom
$9.7M +$152K +1,022 +1%
California Public Employees Retirement System
3
California Public Employees Retirement System
California
$2.29M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$2.27M -$42.3K -285 -2%
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$146K -$434K -2,922 -71%
Squarepoint
6
Squarepoint
New York
$142K +$172K +1,156 New
BlackRock
7
BlackRock
New York
$120K +$5.79K +39 +4%
Creative Planning
8
Creative Planning
Kansas
$102K +$124K +834 New
Morgan Stanley
9
Morgan Stanley
New York
$41K +$37K +249 +323%
UBS Group
10
UBS Group
Switzerland
$30K +$6.53K +44 +22%
Deutsche Bank
11
Deutsche Bank
Germany
$24K +$28.8K +194 New
CMBA
12
C.M. Bidwell & Associates
Hawaii
$19K – – –
Bank of Montreal
13
Bank of Montreal
Ontario, Canada
$9K +$11K +74 +7,400%
CSS
14
Cubist Systematic Strategies
Connecticut
$6K -$12K -81 -64%
PHK
15
Point72 Hong Kong
Hong Kong
$3K – – –
Wells Fargo
16
Wells Fargo
California
$2K – – –
TRCT
17
Tower Research Capital (TRC)
New York
$2K +$2.97K +20 New
Bank of America
18
Bank of America
North Carolina
$1K +$1.78K +12 New
Millennium Management
19
Millennium Management
New York
– -$421K -2,862 Closed
PAM
20
Prudence Asset Management
Hong Kong
– -$272K -1,875 Closed
MWNA
21
Marshall Wace North America
New York
– -$174K -1,182 Closed
DIM
22
DC Investments Management
Virginia
– -$122K -829 Closed
Goldman Sachs
23
Goldman Sachs
New York
– -$98K -664 Closed
LCM
24
Laurion Capital Management
New York
– -$92K -625 Closed
RWP
25
RWA Wealth Partners
Massachusetts
– -$1K -9 Closed
1
2

BTAI Hedge Fund Activity: Q3 2018 in Review

19 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q3 2018, worth a combined $25M — down 27% from $34.2M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of BTAI and 6 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 5 added.

The largest buyer was Squarepoint, opening a new position worth an estimated $172K. The largest seller was Fidelity Investments, cutting an estimated $3.23M.

  • 19 institutional investors held BioXcel Therapeutics (BTAI) as of Q3 2018, down from 20 in Q2 2018.
  • Funds reported $25M of BioXcel Therapeutics stock for Q3 2018, down 27% quarter-over-quarter.
  • 6 funds opened new BioXcel Therapeutics positions in Q3 2018 and 7 closed out, a net change of -1 holder.
  • The largest BioXcel Therapeutics buyer in Q3 2018 was Squarepoint, an estimated $172K added.
  • The largest BioXcel Therapeutics seller in Q3 2018 was Fidelity Investments, an estimated $3.23M sold.

Based on aggregated 13F filings for Q3 2018.